English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/214855
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Brain Angiogenesis Induced by Nonviral Gene Therapy with Potential Therapeutic Benefits for Central Nervous System Diseases

AuthorsGallego, Idoia; Villate-Beitia, Ilia; Soto-Sánchez, Cristina; Menéndez, Margarita ; Grijalvo, Santiago ; Eritja Casadellà, Ramón ; Martínez-Navarrete, Gema; Humphreys, Lawrence; López-Méndez, Tania; Puras, Gustavo; Fernández, Eduardo; Pedraz, José Luis
KeywordsNonviral vector
Niosomes
Gene therapy
VEGF
Angiogenesis
Central nervous system
Issue Date15-Apr-2020
PublisherAmerican Chemical Society
CitationMolecular Pharmaceutics 17 (6): 1848–1858 (2020)
AbstractGene therapy employing nanocarriers represents a promising strategy to treat central nervous system (CNS) diseases, where brain microvasculature is frequently compromised. Vascular endothelial growth factor (VEGF) is a key angiogenic molecule; however, its in vivo administration to the CNS by nonviral gene therapy has not been conducted. Hence, we prepared and physicochemically characterized four cationic niosome formulations (1–4), which were combined with pVEGF-GFP to explore their capacity to transfer the VEGF gene to CNS cells and achieve angiogenesis in the brain. Experiments in primary neuronal cells showed successful and safe transfection with niosome 4, producing double levels of biologically active VEGF in comparison to the rest of the formulations. Intracortical administration of niosome 4 based nioplexes in mouse brain validated the ability of this nonviral vector to deliver the VEGF gene to CNS cells, inducing brain angiogenesis and emerging as a promising therapeutic approach for the treatment of CNS diseases.
Publisher version (URL)https://doi.org/10.1021/acs.molpharmaceut.9b01213
URIhttp://hdl.handle.net/10261/214855
DOIhttp://dx.doi.org/10.1021/acs.molpharmaceut.9b01213
Appears in Collections:(IQAC) Artículos
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.